ExpressPoints: Personalizing Therapy With Factor VIII Prophylaxis in Hemophilia A

Download this summary slideset with essential expert insights on the clinical management of patients with hemophilia A.
Michael Callaghan, MD
Miguel A. Escobar, MD
Guy A. Young, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 252 KB
Released: November 5, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Takeda Pharmaceuticals USA, LLC

Related Content

Dr. Corey S. Cutler shares his views on current and future graft-vs-host disease (GVHD) therapies in this commentary from Clinical Care Options (CCO)

Corey S. Cutler, MD, MPH, FRCPC Released: April 27, 2021

Interactive online tool providing expert management recommendations for β-thalassemia from Clinical Care Options (CCO)

Jeanne Boudreaux, MD person default Stephanie A. Fritch Lilla, MD Janet L. Kwiatkowski, MD, MSCE Sujit Sheth, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: April 22, 2021 Expired: April 21, 2022

On-demand Webcast updated with data from ASH 2020 with expert faculty discussing recent data on management of hemophilia A, presented by Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Michael Callaghan, MD person default Rebecca Kruse-Jarres, MD, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: February 25, 2021 Expired: February 24, 2022

Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD: top picks of nonmalignant hematology studies from ASH 2020 as reported by CCO

Hanny Al-Samkari, MD Mark A. Schroeder, MD Sujit Sheth, MD Released: February 24, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue